Correlation Between Fidelity Advisor and Oramed Pharmaceuticals

Can any of the company-specific risk be diversified away by investing in both Fidelity Advisor and Oramed Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Fidelity Advisor and Oramed Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Fidelity Advisor Stock and Oramed Pharmaceuticals, you can compare the effects of market volatilities on Fidelity Advisor and Oramed Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Fidelity Advisor with a short position of Oramed Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Fidelity Advisor and Oramed Pharmaceuticals.

Diversification Opportunities for Fidelity Advisor and Oramed Pharmaceuticals

0.3

Correlation Coefficient

Fidelity Advisor  Oramed Pharmaceuticals

Weak diversification

The 3 months correlation between Fidelity and Oramed is 0.3. Overlapping area represents the amount of risk that can be diversified away by holding Fidelity Advisor Stock and Oramed Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Oramed Pharmaceuticals and Fidelity Advisor is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Fidelity Advisor Stock are associated (or correlated) with Oramed Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Oramed Pharmaceuticals has no effect on the direction of Fidelity Advisor i.e., Fidelity Advisor and Oramed Pharmaceuticals go up and down completely randomly.

Pair Corralation between Fidelity Advisor and Oramed Pharmaceuticals

Assuming the 90 days horizon Fidelity Advisor Stock is expected to generate 0.32 times more return on investment than Oramed Pharmaceuticals. However, Fidelity Advisor Stock is 3.14 times less risky than Oramed Pharmaceuticals. It trades about -0.15 of its potential returns per unit of risk. Oramed Pharmaceuticals is currently generating about -0.19 per unit of risk. If you would invest  4,108  in Fidelity Advisor Stock on January 26, 2024 and sell it today you would lose (124.00) from holding Fidelity Advisor Stock or give up 3.02% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Weak
Accuracy	95.45%
Values	Daily Returns

Fidelity Advisor Stock  vs.  Oramed Pharmaceuticals

Fidelity Advisor Stock

Risk-Adjusted Performance

6 of 100

Modest

Compared to the overall equity markets, risk-adjusted returns on investments in Fidelity Advisor Stock are ranked lower than 6 (%) of all funds and portfolios of funds over the last 90 days. In spite of fairly strong fundamental indicators, Fidelity Advisor is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors.

Oramed Pharmaceuticals

Risk-Adjusted Performance

2 of 100

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in Oramed Pharmaceuticals are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. Even with relatively weak primary indicators, Oramed Pharmaceuticals may actually be approaching a critical reversion point that can send shares even higher in May 2024.

Pair Trading with Fidelity Advisor and Oramed Pharmaceuticals

The main advantage of trading using opposite Fidelity Advisor and Oramed Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Fidelity Advisor position performs unexpectedly, Oramed Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Oramed Pharmaceuticals will offset losses from the drop in Oramed Pharmaceuticals' long position.

The idea behind Fidelity Advisor Stock and Oramed Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.